2 citations
,
January 1993 Trichohyalin is a versatile protein involved in hair and skin structure.
Thymosin β4 helps with healing, inflammation, and organ protection.
8 citations
,
September 2022 in “Human genomics” Key genes and pathways involved in thyroid eye disease were identified, aiding potential treatment and diagnosis.
November 2019 in “British Journal of Dermatology” FOL-005 peptide may help treat excessive hair growth safely.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
116 citations
,
April 1986 in “The journal of cell biology/The Journal of cell biology” Trichohyalin is a protein in hair follicles that helps form hair filaments.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
42 citations
,
September 1985 in “British Journal of Dermatology” Trichothiodystrophy causes abnormal protein deposits and distortion in hair follicles.
72 citations
,
May 1993 in “The Journal of Cell Biology” Trichohyalin in sheep hair follicles may help with structure and calcium binding.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
September 2025 in “Stem Cell Research & Therapy” TAZ boosts fat cell formation in goat stem cells by activating a specific signaling pathway.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
January 2023 in “Indian dermatology online journal” A child with trichothiodystrophy also had autoimmune thyroiditis and anemia, which is a new finding.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
108 citations
,
October 2003 in “Journal of biological chemistry/The Journal of biological chemistry” Trichohyalin makes hair follicles stronger.
20 citations
,
March 2014 in “Molecular Endocrinology” NFIB and STAT5 work together to control specific genetic programs in cells.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
November 2025 in “Journal of Investigative Dermatology” January 2006 in “Benzina: Revista d'excepcions culturals” Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
January 2015 in “International Journal of Pharma and Bio Sciences” Tridax procumbens is a versatile herb with many health benefits.
3 citations
,
January 2016 in “Chemical sciences journal” Tridax procumbens plant extracts, especially from ethanol, have strong antibacterial effects and contain beneficial compounds like flavonoids and tannins.
28 citations
,
January 2016 in “Vitamins and hormones” Thymosin β4 helps improve skin healing and reduce scarring.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
8 citations
,
January 2019 in “Annals of Dermatology” Bilobetin may help reduce acne by decreasing sebum production.
18 citations
,
November 2016 in “Transgenic research” Overexpressing Tβ4 in cashmere goats improves hair fiber traits and increases cashmere yield.
19 citations
,
July 1997 in “British Journal of Dermatology” LHTric-1 is a specific antibody useful for studying hair and nail formation.
59 citations
,
September 2003 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Epitestosterone may counteract testosterone's effects and has roles in body processes like prostate growth and hair distribution.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.